Arcus Biosciences Inc.（RCUS）与Aveo Pharmaceuticals已就抗癌药物替沃扎尼（tivozanib）的供应达成协议。根据协议条款，Aveo将负责提供该药物，而Arcus将资助并主导相关临床研究。
值得关注的是，双方在合作中均保留了各自对相关化合物的完整权利。这一安排为两家公司在未来探索其他潜在开发路径保留了灵活性。
此次合作旨在推进替沃扎尼在特定癌症适应症中的临床开发。双方资源的整合有望加速该疗法的研究进程。
Arcus Biosciences Inc.（RCUS）与Aveo Pharmaceuticals已就抗癌药物替沃扎尼（tivozanib）的供应达成协议。根据协议条款，Aveo将负责提供该药物，而Arcus将资助并主导相关临床研究。
值得关注的是，双方在合作中均保留了各自对相关化合物的完整权利。这一安排为两家公司在未来探索其他潜在开发路径保留了灵活性。
此次合作旨在推进替沃扎尼在特定癌症适应症中的临床开发。双方资源的整合有望加速该疗法的研究进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.